{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:11:25Z","timestamp":1790241085200,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e30862","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T12:50:01Z","timestamp":1715172601000},"page":"e30862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns"],"prefix":"10.1016","volume":"10","author":[{"given":"Paul-R\u00e9mi","family":"Petit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-2249","authenticated-orcid":false,"given":"Franck","family":"Touret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9lim","family":"Driouich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2318-9662","authenticated-orcid":false,"given":"Maxime","family":"Cochin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orn\u00e9llie","family":"Bernadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-783X","authenticated-orcid":false,"given":"Caroline","family":"Laprie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Piorkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fraisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sj\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-8116","authenticated-orcid":false,"given":"Charles E.","family":"Mowbray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Escudi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-9289","authenticated-orcid":false,"given":"Ivan","family":"Scandale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"de Lamballerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Nougair\u00e8de","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e30862_bib1","doi-asserted-by":"crossref","DOI":"10.1358\/dnp.2009.22.2.1343228","article-title":"The value of drug repositioning in the current pharmaceutical market","volume":"22","author":"Tobinick","year":"2009","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.heliyon.2024.e30862_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.heliyon.2024.e30862_bib3","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013105","article-title":"A comparative analysis of remdesivir and other repurposed antivirals against SARS\u2010CoV\u20102","volume":"13","author":"Simonis","year":"2021","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.heliyon.2024.e30862_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2133","article-title":"Remdesivir: a beacon of hope from Ebola virus disease to COVID \u201019","volume":"30","author":"Nili","year":"2020","journal-title":"Rev. Med. Virol"},{"key":"10.1016\/j.heliyon.2024.e30862_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0006-291X(74)90864-X","article-title":"N4-hydroxycytidine \u2014 a new mutagen of a base analogue type","volume":"56","author":"Popowska","year":"1974","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2024.e30862_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","article-title":"Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture","volume":"47","author":"Stuyver","year":"2003","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.heliyon.2024.e30862_bib7","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1128\/AAC.01598-05","article-title":"Inhibition of human coronavirus NL63 infection at early stages of the replication cycle","volume":"50","author":"Pyrc","year":"2006","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.heliyon.2024.e30862_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/095632020401500102","article-title":"Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and \u03b2-D-N 4 -hydroxycytidine","volume":"15","author":"Barnard","year":"2004","journal-title":"Antivir. Chem. Chemother"},{"key":"10.1016\/j.heliyon.2024.e30862_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.heliyon.2024.e30862_bib10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3851\/IMP2229","article-title":"Antiviral activity of nucleoside analogues against norovirus","volume":"17","author":"Costantini","year":"2012","journal-title":"Antivir. Ther"},{"key":"10.1016\/j.heliyon.2024.e30862_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104597","article-title":"The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection","volume":"171","author":"Painter","year":"2019","journal-title":"Antivir. Res"},{"key":"10.1016\/j.heliyon.2024.e30862_bib12","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/slct.201703052","article-title":"Selective inhibition of enterovirus A species members' reproduction by furano[2, 3- d ]pyrimidine nucleosides revealed by antiviral activity profiling against (+)ssRNA viruses","volume":"3","author":"Kozlovskaya","year":"2018","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.heliyon.2024.e30862_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02395-16","article-title":"Characterization of \u03b2-d-N4-hydroxycytidine as a novel inhibitor of Chikungunya virus","volume":"61","author":"Ehteshami","year":"2017","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.heliyon.2024.e30862_bib14","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.3390\/v7122934","article-title":"Identification of a new ribonucleoside inhibitor of Ebola virus replication","volume":"7","author":"Reynard","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e30862_bib15","doi-asserted-by":"crossref","first-page":"eaax5866","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e30862_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103595","article-title":"The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model","volume":"72","author":"Abdelnabi","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2024.e30862_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.heliyon.2024.e30862_bib18","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/microorganisms10071475","article-title":"The combination of molnupiravir with nirmatrelvir or GC376 has a synergic role in the inhibition of SARS-CoV-2 replication in vitro","volume":"10","author":"Gidari","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.heliyon.2024.e30862_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e30862_bib20","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41467-021-22580-8","article-title":"Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model","volume":"12","author":"Rosenke","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30862_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105122","article-title":"A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents","volume":"192","author":"Do","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2024.e30862_bib22","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1038\/s41467-022-32045-1","article-title":"SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model","volume":"13","author":"Lieber","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30862_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105430","article-title":"Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice","volume":"208","author":"Jeong","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2024.e30862_bib24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e30862_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","volume":"297","author":"Gordon","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e30862_bib26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.heliyon.2024.e30862_bib27","article-title":"Covid-19: FDA expert panel recommends authorising molnupiravir but also voices concerns","volume":"n2984","author":"Dyer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2024.e30862_bib28","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","article-title":"Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model","volume":"12","author":"Driouich","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30862_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104148","article-title":"Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2","volume":"82","author":"Driouich","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2024.e30862_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2020.100059","article-title":"Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia","volume":"1","author":"Pizzorno","year":"2020","journal-title":"Cell Reports Medicine"},{"key":"10.1016\/j.heliyon.2024.e30862_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105137","article-title":"Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2","volume":"193","author":"Touret","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2024.e30862_bib32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent ENDPOINTS12","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.heliyon.2024.e30862_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s42003-022-03171-9","article-title":"The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model","volume":"5","author":"Cochin","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.heliyon.2024.e30862_bib34","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114122","article-title":"Attenuation of clinical and immunological outcomes during SARS\u2010CoV\u20102 infection by ivermectin","volume":"13","author":"De Melo","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.heliyon.2024.e30862_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105212","article-title":"Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model","volume":"197","author":"Cochin","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2024.e30862_bib36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41586-020-2558-4","article-title":"Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates","volume":"585","author":"Maisonnasse","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e30862_bib37","doi-asserted-by":"crossref","first-page":"26955","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2\u2212infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e30862_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113058","article-title":"Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro","volume":"150","author":"Jonsdottir","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e30862_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105581","article-title":"Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation","volume":"213","author":"Dichtl","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2024.e30862_bib40","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jiab361","article-title":"Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model","volume":"224","author":"Abdelnabi","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30862_bib41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.heliyon.2024.e30862_bib42","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100043","article-title":"Phase 2\/3 trial of molnupiravir for treatment of covid-19 in nonhospitalized adults","volume":"1","author":"Caraco","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.heliyon.2024.e30862_bib43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e30862_bib54","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e30862_bib44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e30862_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105492","article-title":"Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model","volume":"209","author":"Johnson","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2024.e30862_bib46","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/jac\/dkab318","article-title":"Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study","volume":"76","author":"Khoo","year":"2021","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.heliyon.2024.e30862_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01965-17","article-title":"\u03b2-d-N4-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome","volume":"92","author":"Urakova","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e30862_bib48","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.1038\/s41467-022-34839-9","article-title":"Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial","volume":"13","author":"Donovan-Banfield","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30862_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-023-06649-6","article-title":"A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes","author":"Sanderson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e30862_bib50","doi-asserted-by":"crossref","first-page":"veae001","DOI":"10.1093\/ve\/veae001","article-title":"Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection","volume":"10","author":"Illingworth","year":"2024","journal-title":"Virus Evolution"},{"key":"10.1016\/j.heliyon.2024.e30862_bib51","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","article-title":"SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters","volume":"603","author":"Iida","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e30862_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160108","article-title":"Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model","volume":"7","author":"Rosenke","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.heliyon.2024.e30862_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024068932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024068932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:50:24Z","timestamp":1790239824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024068932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024068932"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30862","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e30862"}}